| Title |
Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report
|
|---|---|
| Published in |
Clinical Rheumatology, March 2018
|
| DOI | 10.1007/s10067-018-4058-6 |
| Pubmed ID | |
| Authors |
Samuel Deshayes, Nicolas Martin Silva, Valérie Chatelet, Sylvain Chantepie, Moglie Le Quintrec, François Comoz, Frank Bridoux, Marie-Agnès Dragon-Durey, Achille Aouba |
| Abstract |
B-cell clones can produce a monoclonal immunoglobulin, which may be responsible for visceral involvements. Kidney involvement is frequent, affecting 20 to 50% of patients with multiple myeloma. One mechanism underlying this involvement is a dysregulation of the complement alternative pathway, leading to C3 glomerulopathies. We report a patient who had a multiple myeloma, C3 glomerulopathy related to factor H autoantibody, and digital ischemia, who was treated successfully with eculizumab, an anti-complement therapy, without any relapse in 2 years of follow-up. |
X Demographics
The data shown below were collected from the profiles of 22 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 3 | 14% |
| United States | 2 | 9% |
| Ukraine | 2 | 9% |
| Maldives | 1 | 5% |
| Chile | 1 | 5% |
| Colombia | 1 | 5% |
| India | 1 | 5% |
| United Kingdom | 1 | 5% |
| Ecuador | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 8 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 59% |
| Scientists | 4 | 18% |
| Science communicators (journalists, bloggers, editors) | 3 | 14% |
| Practitioners (doctors, other healthcare professionals) | 2 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 10 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 20% |
| Lecturer | 1 | 10% |
| Lecturer > Senior Lecturer | 1 | 10% |
| Student > Doctoral Student | 1 | 10% |
| Student > Ph. D. Student | 1 | 10% |
| Other | 1 | 10% |
| Unknown | 3 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 50% |
| Nursing and Health Professions | 1 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 10% |
| Unknown | 3 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 December 2019.
All research outputs
#2,341,633
of 23,028,364 outputs
Outputs from Clinical Rheumatology
#295
of 3,043 outputs
Outputs of similar age
#52,517
of 332,619 outputs
Outputs of similar age from Clinical Rheumatology
#6
of 70 outputs
Altmetric has tracked 23,028,364 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,043 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,619 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 70 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.